Evidence map›Paper›PMID 34046798›Full record

SynthesisInflammopharmacology2021

Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.

Cláudia Monfroni Rocha, Alessandro Menna Alves, Beatriz Fabris Bettanin, Fernanda Majolo, Matthias Gehringer, Stefan Laufer, Márcia Inês Goettert

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Inflammopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. ActivatingFrontiers in immunology · 2024
    Article
  4. Review
  5. The JAK-STAT Signaling Pathway in Epilepsy.Current neuropharmacology · 2023
    Review
  6. Observational
  7. Article
  8. Article
  9. The JAK/STAT signaling pathway: from bench to clinic.Signal transduction and targeted therapy · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Cláudia Monfroni RochaCell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Av. Avelino Talini, 171, Lajeado, RS, 95914-014, Brazil.
Alessandro Menna AlvesSchool of Dentistry, University Center Univates, Lajeado, RS, Brazil.
Beatriz Fabris BettaninCell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Av. Avelino Talini, 171, Lajeado, RS, 95914-014, Brazil.
Fernanda MajoloCell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Av. Avelino Talini, 171, Lajeado, RS, 95914-014, Brazil.
Matthias GehringerCluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', Eberhard Karls Universität Tübingen, Tübingen, Germany.
Stefan LauferDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Márcia Inês GoettertCell Culture Laboratory, Biotechnology Graduate Program, Universidade do Vale do Taquari, Univates, Av. Avelino Talini, 171, Lajeado, RS, 95914-014, Brazil. marcia.goettert@univates.br.ORCID http://orcid.org/0000-0002-3648-5033
Univates · BRBernstein Center for Computational Neuroscience Tübingen · DE

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 420381/2018-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

objectiveOne-third of patients with severe rheumatoid arthritis (RA) do not achieve remission or low disease activity, or they have side effects from cDMARD and bDMARD. They will need a new treatment option such as the small molecule JAK inhibitors. In this systematic review, we evaluate the efficacy and safety data of the current jakinibs: tofacitinib, peficitinib, decernotinib, upadacitinib, baricitinib and filgotinib in patients in whom treatment with conventional or biological disease-modifying antirheumatic drugs (cDMARD and/or bDMARD) failed.

methodsWe searched for randomized controlled trials comparing efficacy and safety of jakinibs for RA treatment using the Web of Science, Scopus, PubMed, and clinicaltrials.gov databases with the terms: "rheumatoid arthritis" OR "arthritis rheumatoid" OR "RA" AND "inhibitor" OR "jak inhibitor" AND "clinical trial" OR "treatment" OR "therapy".

resultsAll jakinibs achieved good results in ACR 20, 50, 70 and with CRP-DAS28 for LDA and remission, upadacitinib showed better results compared to the others. In ESR-DAS28 for remission, tofacitinib achieved the best result. Regarding the safety of all jakinibs, peficitinib, baricitinib and filgotinib did not register deaths in their studies unlike tofacitinib that presented 11 deaths. Despite all benefits of jakinibs, the use in patients with severe liver and kidney disease should be avoided.

conclusionsJakinibs in monotherapy or in combination with methotrexate can be considered a viable alternative in the treatment of moderate-to-severe RA. Even after failures with combination of cDMARDS and bDMARDS, jakinibs demonstrated efficacy.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAzetidinesChemical and Drug Induced Liver InjuryDrug Therapy, CombinationHeterocyclic Compounds, 3-RingHumansJanus Kinase InhibitorsKidney DiseasesMethotrexatePiperidinesPurinesPyrazolesPyrimidinesRandomized Controlled Trials as TopicSulfonamidesAntirheumatic AgentsAzetidinesbaricitinibHeterocyclic Compounds, 3-RingJanus Kinase InhibitorsMethotrexatePiperidinesPurinesPyrazolesPyrimidinesSulfonamidestofacitinibupadacitinibJAK inhibitorsRheumatoid arthritisSmall molecules

Identifiers

PMID34046798
OpenAlexW3165380757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.